NEW YORK (GenomeWeb) — Genetic testing company InVitae has evaluated the clinical performance of a next-generation sequencing-based test for determining hereditary cancer risk and found that it is as good as Myriad Genetics' BRACAnalysis test at identifying variants in the BRCA genes and can also find additional variants that increase the risk of hereditary cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.